The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy

[1]  C. Hurt,et al.  Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT plus C) in esophageal cancer , 2016 .

[2]  A. Matsuda,et al.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis , 2016, Annals of Surgical Oncology.

[3]  J. Furuse,et al.  Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  I. Tannock,et al.  Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Yu-qin Pan,et al.  Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model , 2015, Journal of Translational Medicine.

[6]  U. Langsenlehner,et al.  The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients , 2015, Tumor Biology.

[7]  Eun Hye Kim,et al.  Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[9]  P. Kornprat,et al.  External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients , 2013, PloS one.

[10]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[11]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[12]  A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients , 2013, British Journal of Cancer.

[13]  H. Grabsch,et al.  Oesophageal Chemoradiotherapy in the UK--current practice and future directions. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  C. Hurt,et al.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. , 2013, The Lancet. Oncology.

[15]  S. Clarke,et al.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer , 2012, British Journal of Cancer.

[16]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[17]  C. Hurt,et al.  SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus , 2011, BMC Cancer.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  S. Loibl,et al.  Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis , 2011, BMC Cancer.

[20]  K. Owzar,et al.  The importance of identifying and validating prognostic factors in oncology. , 2010, Seminars in oncology.

[21]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[22]  T. Conroy,et al.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Malthaner,et al.  WITHDRAWN. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. , 2010, The Cochrane database of systematic reviews.

[24]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.